proxyvotesnow.com

Home › Companies › Enanta Pharmaceuticals, Inc. › 2025-2026

Enanta Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Enanta Pharmaceuticals, Inc.’s Form 8-K, filed 2026-03-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 161Asset managers
  • 943Fund votes
  • 2026-03-11Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Enanta Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Enanta Pharmaceuticals, Inc.

These tallies are Enanta Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-03-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Enanta Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-03-11
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Bruce L.A. Carter, Ph.D. 20,289,217---- 4,634,1231,929,393 Majority: yes
Elect Director: Jay R. Luly, Ph.D. 24,728,854---- 194,4861,929,393 Majority: yes
Proposal 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 1,600,000 shares. 19,528,2235,390,8884,229 --1,929,393 Majority: yes
Proposal 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote. 24,228,898692,0792,363 --1,929,393 Majority: yes
Proposal 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2026 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registe 26,825,17326,904656 --0 Majority: yes

Source: Enanta Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-03-12 — read the filing on EDGAR.

How asset managers voted at the Enanta Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 161 asset managers that disclosed a Enanta Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 24,228,898AGAINST: 692,079

Enanta Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”): 24,228,898 for, 692,079 against, per its Form 8-K filed 2026-03-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,019,344 outstanding shares: 83% for, 2% against (86% of the company cast a for/against vote).

The 161 asset managers below cast 97% of the shares they voted on this item FOR (22,839,927 for, 596,717 against).

FOR 97%
FOR: 22,839,927 (97.5%)AGAINST: 596,717 (2.5%)
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE P” at Enanta Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson6,866,9540 00For
BlackRock2,791,4385,171 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.2,772,1950 00For
Vanguard2,287,9010 00For
Deep Track Capital, LP1,956,8670 00For
ACADIAN ASSET MANAGEMENT LLC643,4427,791 00For
GEODE CAPITAL MANAGEMENT, LLC648,0480 00For
Fidelity575,9950 00For
Charles Schwab540,8130 00For
Invesco0499,375 00Against
State Street472,839735 00For
Hillsdale Investment Management Inc.411,4000 00For
Two Sigma208,1520 00For
Northern Trust198,3020 00For
Renaissance190,9270 00For
Goldman Sachs187,5610 00For
MARSHALL WACE, LLP181,2620 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC157,4970 00For
Dimensional132,7870 00For
Stonepine Capital Management, LLC100,0000 00For
DE Shaw98,9060 00For
MELLON INVESTMENTS Corp90,4670 00For
Nuveen86,0560 00For
TIAA84,4340 00For
Equitable66,5640 00For

Showing the 25 largest of 161 asset managers. See all 161 in the interactive database.

2. To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Bruce L.A. Carter, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 20,289,217WITHHELD: 4,634,123

Enanta Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Bruce L.A. Carter, Ph.D.”): 20,289,217 for, 4,634,123 withheld, per its Form 8-K filed 2026-03-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,019,344 outstanding shares: 70% for, 16% withheld (86% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (4,618,162 for, 0 against).

FOR 79%ABSTAIN 21%
FOR: 4,618,162 (78.6%)ABSTAIN: 1,253,727 (21.4%)
Largest asset managers voting on “To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respectiv” at Enanta Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,150,2270 952,4950For
BlackRock1,930,1610 00For
Fidelity563,2740 00For
Charles Schwab270,4050 00For
Invesco00 223,3520Abstain
Dimensional88,2190 00For
Goldman Sachs86,2450 00For
TIAA84,4340 00For
Equitable44,6340 21,9300For
JPMorgan62,5550 00For
QUANTITATIVE MASTER SERIES LLC46,1590 00For
TARGET PORTFOLIO TRUST33,7000 00For
Thrivent27,2690 00For
Brighthouse26,2890 00For
AIG/SunAmerica25,4280 00For
BRIDGEWAY FUNDS INC25,0000 00For
Northern Trust00 22,1220Abstain
Lincoln Financial20,3780 00For
Nationwide17,2100 00For
Franklin Templeton16,9480 00For
Putnam14,8470 00For
Global X00 12,6680Abstain
Bridge Builder Trust12,0960 00For
Pacific Life10,2770 00For
SEI00 9,8300Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Jay R. Luly, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 24,728,854WITHHELD: 194,486

Enanta Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay R. Luly, Ph.D.”): 24,728,854 for, 194,486 withheld, per its Form 8-K filed 2026-03-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,019,344 outstanding shares: 85% for, 0.7% withheld (86% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (5,870,100 for, 0 against).

FOR 99.9%
FOR: 5,870,100 (100.0%)ABSTAIN: 1,789 (0.0%)
Largest asset managers voting on “To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respectiv” at Enanta Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,102,7220 00For
BlackRock1,930,1610 00For
Fidelity563,2740 00For
Charles Schwab270,4050 00For
Invesco223,3520 00For
Dimensional88,2190 00For
Goldman Sachs86,2450 00For
TIAA84,4340 00For
Equitable66,5640 00For
JPMorgan62,5550 00For
QUANTITATIVE MASTER SERIES LLC46,1590 00For
TARGET PORTFOLIO TRUST33,7000 00For
Thrivent27,2690 00For
Brighthouse26,2890 00For
AIG/SunAmerica25,4280 00For
BRIDGEWAY FUNDS INC25,0000 00For
Northern Trust22,1220 00For
Lincoln Financial20,3780 00For
Nationwide17,2100 00For
Franklin Templeton16,9480 00For
Putnam14,8470 00For
Global X12,6680 00For
Bridge Builder Trust12,0960 00For
Pacific Life10,2770 00For
SEI9,8300 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%
FOR: 19,528,223AGAINST: 5,390,888

Enanta Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance unde”): 19,528,223 for, 5,390,888 against, per its Form 8-K filed 2026-03-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,019,344 outstanding shares: 67% for, 19% against (86% of the company cast a for/against vote).

The 49 asset managers below cast 71% of the shares they voted on this item FOR (4,164,148 for, 1,707,741 against).

FOR 71%AGAINST 29%
FOR: 4,164,148 (70.9%)AGAINST: 1,707,741 (29.1%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.” at Enanta Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,148,827953,895 00For
BlackRock1,930,1610 00For
Fidelity554,0559,219 00For
Charles Schwab270,4050 00For
Invesco0223,352 00Against
Dimensional088,219 00Against
Goldman Sachs086,245 00Against
TIAA084,434 00Against
Equitable44,63421,930 00For
JPMorgan62,5550 00For
QUANTITATIVE MASTER SERIES LLC46,1590 00For
TARGET PORTFOLIO TRUST33,7000 00For
Thrivent027,269 00Against
Brighthouse16,7589,531 00For
AIG/SunAmerica025,428 00Against
BRIDGEWAY FUNDS INC025,000 00Against
Northern Trust022,122 00Against
Lincoln Financial020,378 00Against
Nationwide8,4558,755 00Against
Franklin Templeton016,948 00Against
Putnam014,847 00Against
Global X12,6680 00For
Bridge Builder Trust12,0960 00For
Pacific Life10,2770 00For
SEI8,8151,015 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2026 fiscal year.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 26,825,173AGAINST: 26,904

Enanta Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2026 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers ”): 26,825,173 for, 26,904 against, per its Form 8-K filed 2026-03-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,019,344 outstanding shares: 92% for, 0.1% against (93% of the company cast a for/against vote).

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (5,870,874 for, 1,015 against).

FOR 99.9%
FOR: 5,870,874 (100.0%)AGAINST: 1,015 (0.0%)
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting f” at Enanta Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,102,7220 00For
BlackRock1,930,1610 00For
Fidelity563,2740 00For
Charles Schwab270,4050 00For
Invesco223,3520 00For
Dimensional88,2190 00For
Goldman Sachs86,2450 00For
TIAA84,4340 00For
Equitable66,5640 00For
JPMorgan62,5550 00For
QUANTITATIVE MASTER SERIES LLC46,1590 00For
TARGET PORTFOLIO TRUST33,7000 00For
Thrivent27,2690 00For
Brighthouse26,2890 00For
AIG/SunAmerica25,4280 00For
BRIDGEWAY FUNDS INC25,0000 00For
Northern Trust22,1220 00For
Lincoln Financial20,3780 00For
Nationwide17,2100 00For
Franklin Templeton16,9480 00For
Putnam14,8470 00For
Global X12,6680 00For
Bridge Builder Trust12,0960 00For
Pacific Life10,2770 00For
SEI8,8151,015 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Largest Enanta Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Enanta Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 29,019,344 shares outstanding at the time of that meeting.

Top Enanta Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 23.66%
2BlackRock 9.64%
3FARALLON CAPITAL MANAGEMENT, L.L.C. 9.55%
4Vanguard 7.88%
5Deep Track Capital, LP 6.74%
6ACADIAN ASSET MANAGEMENT LLC 2.24%
7GEODE CAPITAL MANAGEMENT, LLC 2.23%
8Fidelity 1.98%
9Charles Schwab 1.86%
10Invesco 1.72%

Reported Enanta Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Enanta Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Janus Henderson Group plc and certain affiliates 12.04% DEF14A
BlackRock 10.70% 13F
Dapice Joshua J. 9.71% 13G
Vanguard Group 7.93% 13F
Farallon Capital Management, LLC 7.31% DEF14A
Krensavage Asset Management, LLC 7.29% DEF14A
Jay R. Luly, Ph.D. 6.03% DEF14A
Deep Track Capital, LP and certain affiliates 5.12% DEF14A
Millennium Management 3.04% 13F
Integrated Core Strategies (US) LLC 2.29% 13G

Percentages above are of 29,019,344 shares outstanding, as reported by Enanta Pharmaceuticals, Inc. on its Form 10-Q dated 2026-02-05 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Enanta Pharmaceuticals, Inc.’s 10-Q dated 2026-02-05. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Enanta Pharmaceuticals, Inc.'s shareholder meeting held 2026-03-11, in the 2025-2026 proxy season, 161 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 943 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS, AS… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Enanta Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-03-12.

Enanta Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).